<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937582</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A00447-34</org_study_id>
    <nct_id>NCT04937582</nct_id>
  </id_info>
  <brief_title>Cognitive and Psychological Disorders After Severe COVID-19 Infection</brief_title>
  <acronym>NEUROCOG-COVID</acronym>
  <official_title>Long Term Cognitive and Psychological Disorders After Severe COVID-19 Infection in Young Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Régional Metz-Thionville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre hospitalier Epinal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopitaux Civils de Colmar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As COVID-19 pandemic is still ongoing, patients follow-up begins to reveal cognitive and&#xD;
      psychological disorders. There are not yet well described, neither their physiopathology.&#xD;
      This study will consist in the detection and characterization of cognitive and psychological&#xD;
      impairments in young patients under 65 years of age who have been hospitalized more than 72&#xD;
      hours for a severe COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initial consecutive screening of patients (&lt;65 years) hospitalized between the 01/10/2020 and&#xD;
      the 01/04/2021 for more than 72 hours for COVID-19 infection in 6 hospitals of the East of&#xD;
      France. If detection of cognitive complaints (QPC scale : Questionnaire of cognitive&#xD;
      complaints), continuation of the study.&#xD;
&#xD;
      Evaluation with cognitive assessments, morphological and functional imaging and EEG will be&#xD;
      done at 9 ± 3 months and 2 years after initial hospitalisation. Data will be collected&#xD;
      concerning social and professional outcome&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of cognitive and psychological disorders 1 year after COVID-19 infection</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Perfomance to cognitive assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of cognitive and psychological disorders 1 year and 2 years after COVID-19 infection</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of patients with confirmed cognitive and/or psychological disorder compared to the total number of patients who completed the QPC scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of cognitive and psychological disorders 1 year after COVID-19 infection</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Perfomance to cognitive assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the prognosis of cognitive and psychological disorders at 2 years according to the proposed medical care</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Cognitive assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the prognosis of cognitive and psychological disorders at 2 years according to the proposed medical care</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Change from baseline in professional status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>Confirmed cognitive disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with abnormal QPC score at screening visit and confirmed cognitive disorder on the neuropsychological assessment during Visit V1.&#xD;
Intervention Completed by MRI (magnetic resonance imaging), EEG (Electroencephalogram) and possible psychiatric evaluation at Visit 1B.&#xD;
Follow-up 2 years after initial hospitalisation (Visit 2 : neuropsychological assessment ; if needed MRI, EEG, lumbar puncture)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Absence of cognitive disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with abnormal QPC score at screening and absence of cognitive disorder on the neuropsychological assessment during Visit V1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cognitive assessment</intervention_name>
    <description>Complete cognitive and psychological assessment</description>
    <arm_group_label>Absence of cognitive disorder</arm_group_label>
    <arm_group_label>Confirmed cognitive disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Imaging</intervention_name>
    <description>Brain MRI&#xD;
Optional: Brain FDG PET (Brain positron emission tomography with F-18 fluorodeoxyglucose)</description>
    <arm_group_label>Confirmed cognitive disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Routine care</intervention_name>
    <description>Electroencephalogram (EEG)&#xD;
Optional: polysomnography, lumbar puncture</description>
    <arm_group_label>Confirmed cognitive disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychiatric evaluation</intervention_name>
    <description>Psychiatric consultation if necessary</description>
    <arm_group_label>Confirmed cognitive disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychiatric evaluation</intervention_name>
    <description>Psychiatric consultation if necessary (before the end of their participation in the study)</description>
    <arm_group_label>Absence of cognitive disorder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 18 and 65 years of age,&#xD;
&#xD;
          -  Patient hospitalized for more than 72 hours (in intensive care or conventional sector)&#xD;
             for a COVID-19 infection defined by a positive PCR (Polymerase Chain Reaction) test&#xD;
             and/or typical aspect on thoracic scanner,&#xD;
&#xD;
          -  Patient hospitalized between 01/10/2020 and 01/04/2021,&#xD;
&#xD;
          -  Patient with suspected cognitive impairment (obtaining a pathologic QPC score) during&#xD;
             the phone screening,&#xD;
&#xD;
          -  Patient having received complete information on the organization of the research and&#xD;
             having given written informed consent (or a third person, independent of the&#xD;
             investigator and the sponsor, in case of inability to read or write),&#xD;
&#xD;
          -  Patient affiliated with a social security plan or beneficiary of such a plan,&#xD;
&#xD;
          -  Patient with a sufficient level of written French comprehension to complete the&#xD;
             cognitive assessment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to travel to perform the BNP or additional tests,&#xD;
&#xD;
          -  Contraindication to perform brain MRI (pacemaker, etc.),&#xD;
&#xD;
          -  Presence of chronic neurological diseases (multiple sclerosis, neurodegenerative&#xD;
             disease, epilepsy) and/or major cognitive disorders (stroke, head trauma)&#xD;
             pre-COVID-19,&#xD;
&#xD;
          -  Presence of psychiatric disorder historys (bipolar or psychotic illness) pre-COVID-19,&#xD;
&#xD;
          -  Patients with very extensive post-COVID-19 brain damage leading to impossibility to&#xD;
             realise cognitive assessment,&#xD;
&#xD;
          -  Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health&#xD;
             Code.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lucie HOPES, MD</last_name>
    <phone>+33383852377</phone>
    <email>l.hopes@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CLAIRE BANASIAK</last_name>
    <email>c.banasiak@chru-nancy.fr</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Dr Thérèse RIVASSEAU JONVEAUX</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID 19 cognitive impairement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

